News articles about Hologic (NASDAQ:HOLX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hologic earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news articles about the medical equipment provider an impact score of 46.4494386611339 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment’s rankings:
- Piper Jaffray Companies Reaffirms “Buy” Rating for Hologic, Inc. (HOLX) (americanbankingnews.com)
- Hologic’s (HOLX) Buy Rating Reaffirmed at Stifel Nicolaus (americanbankingnews.com)
- Gateway Investment Advisers LLC Boosts Stake in Hologic, Inc. (NASDAQ:HOLX) (fumbleboard.com)
- Webster Bank NA Sells 1718 Shares of Hologic, Inc. (NASDAQ:HOLX) (hoyentv.com)
- Hologic, Inc. (HOLX) stock uncovered monthly dynamic performance with growing progress of 0.25% – Stocks Gallery (stocksgallery.com)
A number of brokerages have recently issued reports on HOLX. Stifel Nicolaus reissued a “buy” rating on shares of Hologic in a research note on Friday. Jefferies Group LLC set a $49.00 price objective on Hologic and gave the company a “buy” rating in a research note on Sunday, May 28th. Piper Jaffray Companies reissued a “buy” rating and issued a $51.00 price objective on shares of Hologic in a research note on Friday. Leerink Swann reissued an “outperform” rating and issued a $52.00 price objective on shares of Hologic in a research note on Thursday, March 30th. Finally, Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. Hologic currently has a consensus rating of “Buy” and an average price target of $47.36.
Hologic (NASDAQ HOLX) traded down 1.24% during trading on Monday, hitting $44.61. The stock had a trading volume of 2,992,880 shares. The company has a market capitalization of $12.49 billion, a P/E ratio of 15.99 and a beta of 0.91. Hologic has a 1-year low of $35.15 and a 1-year high of $46.80. The stock’s 50-day moving average price is $44.35 and its 200-day moving average price is $42.22.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.04. Hologic had a net margin of 27.31% and a return on equity of 25.26%. The company had revenue of $715.40 million during the quarter, compared to analyst estimates of $685.24 million. During the same period in the previous year, the business earned $0.47 EPS. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. Analysts expect that Hologic will post $2.01 earnings per share for the current year.
In other Hologic news, Director Lawrence M. Levy sold 9,837 shares of Hologic stock in a transaction that occurred on Wednesday, May 10th. The shares were sold at an average price of $45.34, for a total value of $446,009.58. Following the completion of the sale, the director now owns 40,577 shares of the company’s stock, valued at approximately $1,839,761.18. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Elaine Ullian sold 8,849 shares of Hologic stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $45.28, for a total transaction of $400,682.72. Following the completion of the sale, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $1,078,116.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,240 shares of company stock valued at $4,716,859. 0.79% of the stock is currently owned by insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.